Peer Reviewed Publications

For citations please hit Google Scholar

2023

32. Breast cancer cell secretome analysis to decipher miRNA regulating the tumor microenvironment and discover potential biomarkers. Riley Feser, Reid Opperman, Braydon Nault, Sujit Maiti, Vincent Chen, Mousumi Majumder. Heliyon, Cell Press, 2023. DOI:https://doi.org/10.1016/j.heliyon.2023.e15421

2022

31. Breast Cancer Cell Secretome Analysis to Decipher miRNA Tumor Biology and Discover Potential Biomarkers. Riley Feser, Reid Opperman, Braydon Nault, Sujit Maiti, Vincent Chen, Mousumi Majumder. Preprint. DOI: https://doi.org/10.21203/rs.3.rs-1328838/v1. 

30. Riley Feser, Reid Morgan Opperman, Sujit Maiti, and Mousumi Majumder. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects, 2022. Springer Nature. https://doi.org/10.1007/978-981-16-1247-3_239-1. Feser2022_ReferenceWorkEntry_MicroRNAsTheMasterRegulatorsOf-1.pdf

2021

29. Pri-miR526b and Pri-miR655 Are Potential Blood Biomarkers for Breast Cancer. Mousumi Majumder, Kingsley Chukwunonso Ugwuagbo, Sujit Maiti, Peeyush K Lala, Muriel Brackstone. Cancers, 202113(15), 3838;  https://doi.org/10.3390/cancers13153838

28. Prostaglandin E2 Receptor 4 (EP4) as a Therapeutic Target to Impede Breast Cancer-Associated Angiogenesis and Lymphangiogenesis. De Paz Linares, G.A.; Opperman, R.M.; Majumder, M.; Lala, P.K. Cancers, 2021, 13, 942. https://doi.org/10.3390/cancers13050942. [†, equal contribution].

2020

27. Chemically Induced Hypoxia Enhances miRNA Functions in Breast Cancer. Gervin E, Shin B, Opperman R, Cullen M, Freser R, Maiti S, Majumder M. Cancers 2020, 12(8), 2008; https://doi.org/10.3390/cancers12082008 . [†, equal contribution].

2019

26. miR526b andmiR655 Induce Oxidative Stress in Breast Cancer. Shin B, Freser R, Nault B, Hunter S, Maiti S, Ugwuagbo KC, Majumder M.  International Journal of Molecular Sciences. 2019 Aug 19;20(16). pii: E4039. doi: 10.3390/ijms20164039.

25. Mir526b and Mir655 Promote Tumour Associated Angiogenesis and Lymphangiogenesis in Breast Cancer. Hunter S, Nault B#, Ugwuagbo KC#, Maiti S, Majumder M. Cancers (Basel). 2019 Jul 4;11(7). pii: E938. doi: 10.3390/cancers11070938. [# equal contribution].

24. Tumor suppressor role of cytoplasmic polyadenylation element binding protein 2 (CPEB2) in human mammary epithelial cells. Tordjman J#, Majumder M#, Amiri M, Hasan A, Hess D, Lala PK. BMC Cancer. 2019 Jun 11;19(1):561. doi: 10.1186/s12885-019-5771-5. [# equal contribution first authors].

23. Prostaglandin E2 Promotes Embryonic Vascular Development and Maturation in Zebrafish. Kingsley Chukwunonso Ugwuagbo, Sujit Maiti, Ahmed Omar, Stephanie Hunter*, Braydon Nault*, Caleb Northam, Mousumi Majumder. [*authors contributed equally]. Journal: Biol Open. 2019 Mar 19. pii: bio.039768. doi: 10.1242/bio.039768

2018

22. Roles of prostaglandins in tumor-associated lymphangiogenesis with special reference to breast cancer. Lala PK, Nandi P, Majumder M. Cancer Metastasis Rev. 2018 Jun 1. doi: 10.1007/s10555-018-9734-0. [Epub ahead of print]

21. EP4 as a Therapeutic Target for Aggressive Human Breast Cancer. Majumder M, Nandi P, Omar A, Ugwuagbo KC, Lala PK. Int J Mol Sci. 2018 Mar 29;19(4). pii: E1019. doi: 0.3390/ijms19041019. Review.

20. COX-2 induces oncogenic micro RNA miR655 in human breast cancer. Majumder M, Dunn L, Liu L, Hasan A, Vincent K, Brackstone M, Hess D, Lala PK. Scientific Report. 2018 Jan 10;8(1):327. doi: 10.1038/s41598-017-18612-3. https://www.nature.com/srep/

2017

19. PGE2 promotes breast cancer-associated lymphangiogenesis by activation of EP4 receptor on lymphatic endothelial cells. Nandi P, Girish GV, Majumder M, Xin X, Tutunea-Fatan E, Lala PK. BMC Cancer. 2017 Jan 5;17(1):11. doi: 10.1186/s12885-016-3018-2.

2016

18. COX-2 Induces Breast Cancer Stem Cells via EP4/PI3K/AKT/NOTCH/WNT Axis. Majumder M, Xin X, Liu L, Tutunea-Fatan E, Rodriguez-Torres M, Vincent K, Postovit LM, Hess D, Lala PK. Stem Cells. 2016 Sep;34(9):2290-305. doi: 10.1002/stem.2426. Epub 2016 Jun 27.

2015

17. Sequence and expression variations in 23 genes involved in mitochondrial and non-mitochondrial apoptotic pathways and risk of oral leukoplakia and cancer. Datta S, Ray A, Singh R, Mondal P, Basu A, De Sarkar N, Majumder M, Maiti G, Baral A, Jha GN, Mukhopadhyay I, Panda C, Chowdhury S, Ghosh S, Roychoudhury S, Roy B. Mitochondrion. 2015 Nov;25:28-33. doi: 10.1016/j.mito.2015.09.001. Epub 2015 Sep 21.

16. The role of CCL21/CCR7 chemokine axis in breast cancer-induced lymphangiogenesis.Tutunea-Fatan E, Majumder M, Xin X, Lala PK. Molecular Cancer. 2015 Feb 10;14:35. doi: 10.1186/s12943-015-0306-4.

15. COX-2 Elevates Oncogenic miR-526b in Breast Cancer by EP4 Activation. Majumder M, Landman E, Liu L, Hess D, Lala PK. Molecular Cancer Research. 2015 Jun;13(6):1022-33. doi: 10.1158/1541-7786.MCR-14-0543. Epub 2015 Mar 2.

14. D-loop somatic mutations and ∼5 kb “common” deletion in mitochondrial DNA: important molecular markers to distinguish oral precancer and cancer. Datta S, Chattopadhyay E, Ray JG, Majumder M, Roy PD, Roy B. Tumour Biology. 2015 Apr;36(4):3025-33. doi: 10.1007/s13277-014-2937-2. Epub 2014 Dec 20.

2014

13. Prostaglandin E2 receptor EP4 as the common target on cancer cells and macrophages to abolish angiogenesis, lymphangiogenesis, metastasis, and stem-like cell functions. Majumder M, Xin X, Liu L, Girish GV, Lala PK. Cancer Science. 2014 Sep;105(9):1142-51. doi: 10.1111/cas.12475. Epub 2014 Sep 11.

2013

12. Single nucleotide polymorphism network: a combinatorial paradigm for risk prediction. Das Roy P, Sengupta D, Dasgupta AK, Kundu S, Chaudhuri U, Thakur I, Guha P, Majumder M, Roy R, Roy B. PLoS One. 2013 Sep 11;8(9):e74067. doi: 10.1371/journal.pone.0074067. eCollection 2013.

11. A practical and sensitive method of quantitating lymphangiogenesis in vivo. Majumder M, Xin X, Lala PK. Laboratory Investigation. 2013 Jul;93(7):779-91. doi: 10.1038/labinvest.2013.72. Epub 2013 May 27. https://www.nature.com/labinvest/

2012

10. Association between polymorphisms at N-acetyltransferase 1 (NAT1) & risk of oral leukoplakia & cancer. Majumder M, Ghosh S, Roy B. Indian J Med Res. 2012 Oct;136(4):605-13.

9. Differential haplotype amplification leads to misgenotyping of heterozygote as homozygote when using single nucleotide mismatch primer. De Sarkar N, Majumder M, Roy B. Electrophoresis. 2012 Dec;33(23):3564-73. doi: 10.1002/elps.201200363.

8. Targeting COX-2 and EP4 to control tumor growth, angiogenesis, lymphangiogenesis and metastasis to the lungs and lymph nodes in a breast cancer model. Xin X, Majumder M, Girish GV, Mohindra V, Maruyama T, Lala PK. Laboratory Investigation. 2012 Aug;92(8):1115-28. doi: 10.1038/labinvest.2012.90. Epub 2012 May 28. https://www.nature.com/labinvest/

7. Co-expression of α9β1 integrin and VEGF-D confers lymphatic metastatic ability to a human breast cancer cell line MDA-MB-468LN. Majumder M, Tutunea-Fatan E, Xin X, Rodriguez-Torres M, Torres-Garcia J, Wiebe R, Timoshenko AV, Bhattacharjee RN, Chambers AF, Lala PK. PLoS One. 2012;7(4):e35094. doi: 10.1371/journal.pone.0035094. Epub 2012 Apr 24.

2009

6. Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. Misra C, Majumder M, Bajaj S, Ghosh S, Roy B, Roychoudhury S. Molecular Carcinogenesis. 2009 Sep;48(9):790-800. doi: 10.1002/mc.20523.

5. Variant haplotypes at XRCC1 and risk of oral leukoplakia in HPV non-infected samples. Majumder M, Indra D, Roy PD, Datta S, Ray JG, Panda CK, Roy B. Journal of Oral Pathology & Medicine. 2009 Feb;38(2):174-80. doi: 10.1111/j.1600-0714.2008.00690.x. Epub 2008 Aug 31.

2008

4. Pharmacogenomics of anti-TB drugs-related hepatotoxicity. Roy PD, Majumder M, Roy B. Pharmacogenomics. 2008 Mar;9(3):311-21. doi: 10.2217/14622416.9.3.311. Review.

2007

3. Increased risk of oral cancer in relation to common Indian mitochondrial polymorphisms and Autosomal GSTP1 locus. Datta S, Majumder M, Biswas NK, Sikdar N, Roy B. Cancer. 2007 Nov 1;110(9):1991-9.

2. Polymorphisms at XPD and XRCC1 DNA repair loci and increased risk of oral leukoplakia and cancer among NAT2 slow acetylators. Majumder M, Sikdar N, Ghosh S, Roy B. International Journal of Cancer. 2007 May 15;120(10):2148-56.

2005

1. Increased risk of oral leukoplakia and cancer among mixed tobacco users carrying XRCC1 variant haplotypes and cancer among smokers carrying two risk genotypes: one on each of two loci, GSTM3 and XRCC1 (Codon 280). Majumder M, Sikdar N, Paul RR, Roy B. Cancer Epidemiology Biomarkers and Prevention. 2005 Sep;14(9):2106-12.